VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 37 filers reported holding VERONA PHARMA PLC in Q4 2020. The put-call ratio across all filers is 1.20 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $529,750 | -22.9% | 32,500 | 0.0% | 0.01% | -14.3% |
| Q2 2023 | $687,050 | +5.3% | 32,500 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $652,600 | -26.5% | 32,500 | -4.4% | 0.01% | -30.0% |
| Q4 2022 | $888,420 | +117.2% | 34,000 | -15.0% | 0.01% | +100.0% |
| Q3 2022 | $409,000 | +119.9% | 40,000 | -10.1% | 0.01% | +150.0% |
| Q2 2022 | $186,000 | -22.5% | 44,500 | -7.3% | 0.00% | -33.3% |
| Q1 2022 | $240,000 | -25.7% | 48,000 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $323,000 | +47.5% | 48,000 | +20.0% | 0.00% | 0.0% |
| Q3 2021 | $219,000 | -20.1% | 40,000 | -4.5% | 0.00% | 0.0% |
| Q2 2021 | $274,000 | -21.7% | 41,900 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $350,000 | -49.5% | 41,900 | -57.7% | 0.00% | -63.6% |
| Q4 2020 | $693,000 | +27.2% | 98,951 | +13.2% | 0.01% | +22.2% |
| Q3 2020 | $545,000 | -0.4% | 87,385 | -25.2% | 0.01% | -10.0% |
| Q2 2020 | $547,000 | +53.2% | 116,810 | +34.7% | 0.01% | +42.9% |
| Q1 2020 | $357,000 | – | 86,730 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 2,457,499 | $16,932,000 | 5.79% |
| Aisling Capital Management LP | 1,332,485 | $9,327,000 | 1.60% |
| Ghost Tree Capital, LLC | 810,000 | $5,670,000 | 1.26% |
| Vivo Capital, LLC | 3,048,507 | $21,340,000 | 0.95% |
| NEA Management Company, LLC | 5,108,563 | $35,760,000 | 0.94% |
| Novo Holdings A/S | 2,608,755 | $18,261,000 | 0.78% |
| Samsara BioCapital, LLC | 1,111,112 | $7,778,000 | 0.78% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,033,603 | $7,235,000 | 0.64% |
| RA Capital Management | 5,100,000 | $31,824,000 | 0.44% |
| Orbimed Advisors | 5,694,841 | $39,864,000 | 0.35% |